Zusammenfassung
Die Neurofibromatose Typ 1 ist eine der häufigsten hereditären neurokutanen Erkrankungen,
die wie auch ihre klinisch bekannten Varianten autosomal dominant vererbt wird. Die
Diagnose beruht auf sieben Konsensus-Kriterien des National Institute of Health (1988).
Wir berichten im Folgenden über 2 Patientinnen, die mit typischen kutanen, okulären
und ossären Symptomen in unserer Klinik erstmals an Neurofibromatose Typ 1 erkrankt
diagnostiziert wurden. Die Klinik, die diagnostischen Kriterien sowie der genetische
Hintergrund der Neurofibromatose Typ 1 sind im Folgenden dargestellt.
Abstract
Neurofibromatosis is one of most common inherited autosomal dominant neurocutaneous
diseases which displays certain typical clinical characteristics. The diagnosis is
based on seven criteria set up the National Institutes of Health Consensus Development
Conference (1988). We describe in the following two cases of neurofibromatosis type
1 which were first diagnosed in our clinic. Both patients had the cutaneous, ocular
and osseous symptoms which are typical for this disease. In this report we present
the clinical aspects, the diagnostic criteria as well the genetic backround of neurofibromatosis
type 1.
Literatur
1 Riccardi V M.
The clinical and molecular genetics of Neurofibromatosis-1 and Neurofibromatosis-2. In: Rosenberg RN, Prusiner SB, DiMauro S et al. (eds) The molecular and genetic basis
of neurological disease. Boston; Butterworth-Heinemann 1993: 837-853
2
Colman S D, Wallace M R.
Neurofibromatosis type 1.
Eur J Cancer.
1994;
30
1974-1981
3
Thomas G, Mérel P, Sanson M. et al .
Neurofibromatosis type 2.
Eur J Cancer.
1994;
30 A
1981-1987
4
Schmidt M A, Michels V V, Dedwald G W.
Cases of neurofibromatosis with rearrangements of chromosome 17 involving band 17q11.2.
Am J Hum Genet.
1987;
28
771-777
5
Morrison H, Sherman L S, Legg J. et al .
The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth
through interactions with CD44.
Genes Dev.
2001;
15
968-980
6
Sun C-X, Robb V A, Gutmann D H.
Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation.
J Cell Science.
2002;
115
3991-4000
7
Trofatter J A, MacCollin M M, Rutter J L. et al .
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis
2 tumor suppressor.
Cell.
1993;
72
1-20
8
Cichowski K, Jacks T.
NF1 tumor supressor gene function: narrowing the gap.
Cell.
2001;
105
593-604
9
McCormick F.
Ras signaling and NF1.
Curr Opinion Genes Dev.
1995;
5
51-55
10
Riccardi V M.
The multiple forms of neurofibromatosis.
N Engl J Med.
1982;
305
1617-1627
11
Jung E G.
Segmental Neurofibromatosis (NF5).
Neurofibromatosis,.
1988;
1
306-311
12
National Institutes of Health Consensus Developement Conference .
Neurofibromatosis: conference statement.
Arch Neurol.
1988;
45
575-578
13
Lázaro C, Ravenna A, Gaona A, Volpini V, Estivill X.
Neurofibromatosis type 1 due to germ - line mosaicism in a clinically normal father.
N Engl J Med.
1994;
331
403-1407
14 Köhler B. Neurofibromatose im Kindesalter. Stuttgart; Wiss. Verlagsgesellschaft
1990
15
Ridley A J, Paterson H F, Noble M, Land H.
Ras - mediated cell cycle arrest is altered by nuclear oncogenes to induce Schwann
cell transformation.
EMBO J.
1988;
7
1635-1645
Dr. med. Anette Zimpfer
c/o Praxis Dres. Angela und Helmut Wirth · Hautärzte/Allergologie und Lasertherapie
Rohrbacher Str. 9 · 69115 Heidelberg